Thinking of joining a study?

Register your interest

Become a volunteer?

NCT07150806 | RECRUITING | Recurrent Meningioma

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
Sponsor:

Joshua Palmer

Information provided by (Responsible Party):

Joshua Palmer

Brief Summary:

This phase I/II tests the safety, side effects, best dose and how well giving RYZ101 works for the treatment of patients with intracranial meningioma that is growing, spreading, or getting worse (progressive) or that has come back after a period of improvement (recurrent). RYZ101 is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177-dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving RYZ101 may be safe, tolerable and/or effective in treating patients with progressive or recurrent intracranial meningioma.

Condition or disease

Recurrent Meningioma

Intervention/treatment

Actinium Ac 225 DOTATATE RYZ101

Biospecimen Collection

Computed Tomography

Echocardiography Test

Gallium Ga 68-DOTATATE

L-lysine/L-arginine-containing Amino Acid

Magnetic Resonance Imaging

Multigated Acquisition Scan

Positron Emission Tomography

Somatostatin Receptor Positron Emission Tomography

Phase

PHASE1

PHASE2

Detailed Description:

PRIMARY OBJECTIVE: I. To estimate the efficacy of 225Ac-DOTATATE (RYZ101) therapy in the treatment of patients with progressive or recurrent grade 1-3 intracranial meningioma as measured by the progression free survival at 6 months. SECONDARY OBJECTIVES: I. To evaluate the objective response rate (ORR) by standard of care brain magnetic resonance imaging (MRI) at 6 months and gallium Ga 68-DOTATATE (68Ga-DOTATATE) positron emission tomography (PET) imaging at 1 year. II. To determine the overall survival (by grade cohort) in patients with progressive / recurrent meningioma during or after treatment with RYZ101. III. To determine the progression-free survival (by grade cohort) in patients with progressive / recurrent meningioma during or after treatment with RYZ101. IV. To determine the toxicity rate in patients with progressive / recurrent meningioma during or after treatment with RYZ101. V. To perform semiquantitative analysis of PET standardized uptake value (SUV) uptake and compare to the background for treatment response assessment and as a potential biomarker of response and prognosis. OUTLINE: Patients receive RYZ101 intravenously (IV) and amino acids, with L-arginine and L-lysine, IV on day 1 of each cycle. Cycles repeat every 8 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients receive Ga 68-DOTATATE IV and undergo PET scan or somatostatin receptor (SSTR) PET scan, computed tomography (CT) scan, MRI and undergo blood and urine sample collection and may undergo echocardiography or multigated acquisition (MUGA) scan throughout the study. After completion of study treatment, patients are followed up every 3 months for 1 year.

Study Type : INTERVENTIONAL
Estimated Enrollment : 30 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : Progressive/Recurrent Intracranial Meningioma Treated With SSTR-Targeted Alpha Emitter RYZ101 (PRIMe-STAR)
Actual Study Start Date : 2025-11-13
Estimated Primary Completion Date : 2026-12-31
Estimated Study Completion Date : 2026-12-31

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Male or female patients of age \> 18 years
  • * Patients with 68Ga-DOTATATE positive recurrent or progressive meningiomas, any World Health Organization (WHO) grade, who have progressed after first line treatment.
  • * For Grade I meningioma, patients must have either
    • * Progressive disease after at least surgical resection and radiotherapy, as defined as an increase in size of the measurable primary lesion (bidirectional area) on imaging by 25% or more between scans separated by no more than 12 months; or
    • * Progressive residual tumor after maximal safe resection, located at or near critical organs at-risk and considered to be high-risk for radiation injury by the treating investigator. Prior external beam radiotherapy is not required for these subjects.
    • * For Grade II or III meningioma, subjects must have either
      • * Progressive disease after at least surgical resection and radiotherapy, as defined as an increase in size of the measurable primary lesion (bi-directional area) on imaging by 25% or more between scans separated by no more than 12 months or
      • * Residual measurable disease after prior surgery without requirement of progression, or
      • * Unsuitable for, or decline other standard of care treatment.
      • * Positive 68Ga-DOTATATE uptake on PET/CT at baseline, defined as target lesion uptake higher than the background with SUV ratios adjusted to the liver uptake (Krenning score ≥ 2)
      • * Presence of measurable disease defined as at least one lesion measuring ≥ 5 mm in at least one dimension by contrast-enhanced MRI performed within 30 days prior to study registration
      • * Multifocal disease allowed but limited to ≤ 3 measurable intracranial lesions on the most recent post-contrast MRI
      • * There is no limit on the number of prior surgeries, radiation therapy, radiosurgery, systemically administered therapeutic agents or theranostic agents
      • * For patients treated with external beam radiation, interstitial brachytherapy or radiosurgery, an interval ≥ 24 weeks must have elapsed from completion from these therapies to registration unless there is histopathologic confirmation of recurrent tumor or there is new enhancing tumor outside the radiation field (beyond the high dose region or the 80% isodose line)
      • * An interval of ≥ 28 days (or 5 half-lives, whichever is shorter) from prior cytotoxic chemotherapy (6 weeks from nitrosoureas), biologic agent, investigational agent or any other systemic agent prescribed for the purpose of treating meningioma
      • * An interval of ≥ 28 days from craniotomy and ≥ 7 days from stereotactic biopsy
      • * Patients must be willing and able to undergo regular MRI scans of the brain
      • * Patients must have recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade ≤ 1 or pretreatment baseline from clinically significant adverse events related to prior therapy (exclusions include alopecia, laboratory values listed per inclusion criteria, lymphopenia, sensory neuropathy ≤ grade 2, or other ≤ grade 2 not constituting a safety risk based on the investigator's judgment)
      • * Any neurological symptoms must be stable for at least 28 days prior to enrollment and patients should not require escalating doses of steroids to control neurological symptoms (stable low dose maintenance steroids at ≤ 8 mg dexamethasone or equivalent are allowed)
      • * Sufficient renal function, as evidenced by creatinine clearance (CrCl) ≥ 60 mL/min calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
      • * Hemoglobin concentration ≥ 5.0 mmol/L (≥ 8.0 g/dL)
      • * Note: Colony-stimulating factors, platelet-production stimulators and/or transfusions within 4 weeks prior to screening and first dose of study treatment are not permitted to meet these criteria
      • * Absolute neutrophil count (ANC) ≥ 1000 cells/µL (≥ 1000 cells/mm\^3)
      • * Note: Colony-stimulating factors, platelet-production stimulators and/or transfusions within 4 weeks prior to screening and first dose of study treatment are not permitted to meet these criteria.
      • * Platelets \> 100 × 10\^9/L (100 × 10\^3/mm\^3)
      • * Note: Colony-stimulating factors, platelet-production stimulators and/or transfusions within 4 weeks prior to screening and first dose of study treatment are not permitted to meet these criteria.
      • * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN) (or ≤ 5 × ULN if presence of liver metastases)
      • * Total bilirubin ≤ 3 × ULN
      • * Serum albumin ≥ 3.0 g/dL
      • * Adequate coagulation function, defined by international normalized ratio (INR) or prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN, unless subject is receiving anticoagulant therapy and PT or aPTT is within therapeutic range of intended use of anticoagulants
      • * For women of childbearing potential (WOCBP)
        • * Negative pregnancy test within 48 hours prior to the first dose of study treatment
        • * Agreement to use barrier contraception and a second form of highly effective contraception while receiving study treatment and for 7 months following their last dose of study treatment. Alternatively, total abstinence is also considered a highly effective contraception method when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
        • A woman is considered to be of childbearing potential if she is postmenarche, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea \[no menstrual bleeding of any kind, including menstrual period, irregular bleeding, spotting, etc.\] with no identified cause other than menopause), and has not undergone surgical sterilization (total hysterectomy, or bilateral tubal ligation or bilateral oophorectomy at least 6 weeks before first dose of study treatment)
        • * Sexually active male subjects must use a condom during intercourse while receiving RYZ101 and for at least 120 days after the last dose of the study treatment and should not father a child during this period.
        • * Male study subjects whose sexual partners are WOCBP must also agree to use a second form of highly effective contraception while receiving RYZ101 and for at least 4 months following their last dose. Alternatively, total abstinence is also considered a highly effective contraception method when this is in line with the preferred and usual lifestyle of the subject.
        • * Vasectomized men are also required to use a condom during intercourse, including with a male partner, to prevent delivery of the drug via seminal fluid.
        Exclusion Criteria
        • * Eastern Cooperative Oncology Group (ECOG) performance status \> 2
        • * Received radiation therapy to the brain in last 24 weeks
        • * History of hypersensitivity or allergy to Actinium Ac-225 (225Ac), Gallium Ga 68 (68Ga), Copper Cu 64 (64Cu), octreotate, or any of the excipients of DOTATATE imaging agents
        • * Prior radiopharmaceutical therapies (RPT), including radioembolization
        • * Prior solid organ or bone marrow transplantation
        • * Any toxicities from prior treatments that have not recovered to CTCAE grade ≤1, except for alopecia
        • * Significant cardiovascular disease, defined as
          • * New York Heart Association (NYHA) Class ≥ II heart failure.
          • * Known left ventricular ejection fraction (LVEF) \< 50%.
          • * History of myocardial infarction, acute coronary syndrome, or coronary angioplasty/stenting/bypass within the last 6 months.
          • * QT interval corrected for heart rate using Fridericia's formula (QTcF) \> 470 ms, demonstrated by the average value of 3 consecutive electrocardiograms (ECGs).
          • * Resistant hypertension, defined as persistent uncontrolled blood pressure (BP) \> 140/90 mmHg while on optimal doses of at least 3 antihypertensive medications with 1 being a diuretic. Patients with baseline hypertension may be eligible after initiation of antihypertensive therapy
          • * Uncontrolled diabetes mellitus as defined by hemoglobin A1C (HgB A1c) \> 8% in patients with known diagnosis of diabetes mellitus)
          • * Liver cirrhosis
          • * Pregnancy or lactation
          • * Unable to understand or unwilling to sign an Institutional review board approved written informed consent document
          • * Current somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study
RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

Location Details

NCT07150806

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Ohio

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, United States, 43210